Overview Drugs Mechanism of Action Toxicity Cyclophosphamide and ifosfamide Crosslinks DNA Hemorrhagic cytitis and myelosupression Nitrosoureas Crosslinks DNA Dizziness and ataxia Busulfan Alkylates DNA Pulmonary fibrosis and hyperpigmentation Cyclophosphamide and Ifosfamide Mechanism covalently crosslinks DNA at guanine N7 position between strands and within strands requires bioactivation by liver Clinical use non-Hodgkin's lymphoma breast cancer ovarian cancer immunosuppression Toxicity hemorrhagic cystitis prevent with mesna or N-acetylcysteine thiol group binds acrolein, a toxic metabolite myelosuppression Nitrosoureas (Carmustine, Lomustine, Semustine, and Streptozocin) Mechanism crosslinks DNA crosses BBB and enters CNS requires bioactivation Clinical use brain tumors including glioblastoma multiforme Toxicity CNS toxicity dizziness ataxia Busulfan Mechanism alkylates DNA Clinical use CML was gold standard before imatinib was discovered hematopoietic stem cell transplants used for bone marrow ablation Toxicity pulmonary fibrosis hyperpigmentation
QUESTIONS 1 of 2 1 2 Previous Next Sorry, this question is for PEAK Premium Subscribers only Upgrade to PEAK (M1.ON.13.119) A 52-year-old male with follicular non-Hodgkin lymphoma undergoes chemotherapy. He develops suprapubic pain and hematuria. Which of the following compounds is most likely responsible for this patient's symptoms? QID: 101429 Type & Select Correct Answer 1 Cyclophosphamide 80% (104/130) 2 Cisplatin 5% (7/130) 3 Mesna 3% (4/130) 4 Bleomycin 7% (9/130) 5 Carmustine 1% (1/130) M 4 Question Complexity E Question Importance Select Answer to see Preferred Response SUBMIT RESPONSE 1 Review Tested Concept Review Full Topic
All Videos (0) Oncology | Alkylating Agents Oncology - Alkylating Agents Listen Now 9:39 min 10/18/2022 8 plays 0.0 (0)